How do you pay?

How to pay the least

Ask for the cash price

Cayston

The FDA has approved a generic, but it isn’t in pharmacies yet.

  1. Ask your pharmacy for Cayston’s cash price, and one or two other pharmacies too.
  2. Cayston’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Cayston Patient Assistance Program. Or call 1-877-722-9786.

See if you qualify 

Compare every option

Question
Brand nameCayston
Authorized genericaztreonam
Regular genericaztreonam
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNot in stores yet
Same as Cayston?
The original
–
–

Brand nameThe maker’s card

Cayston Co-pay Savings Program (Cayston Access Program)

Savings card from Gilead Sciences

No insuranceNeeds insuranceNo cash price listed.
Insurance $10 or less a fill

The card takes up to $8,000 a year off your co-pay.

Sign up on cayston.com 

Or call 1-877-722-9786.

In the maker’s words

“People with private insurance pay no more than $10 per fill.”

From the maker’s offer on cayston.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Cayston itself, from the same company, sold without the brand name, and usually for less. For now Cayston is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

The FDA has approved a generic, but it isn’t in pharmacies yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Source: the FDA label for Cayston (Gilead Sciences, Inc.), December 1, 2025. Full label on DailyMed 

Good to know